FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783012969> ?p ?o ?g. }

• W2783012969 endingPage "322" @default.
• W2783012969 startingPage "322" @default.
• W2783012969 abstract "Abstract BACKGROUND RESPONSE is an ongoing, multicenter, open-label, phase 3 trial comparing the efficacy and safety of rux with BAT in patients (pts) with PV who are resistant to or intolerant of hydroxyurea (HU). Primary analysis and 80-week (wk) follow-up results from RESPONSE have been published previously. The 80-wk follow-up data confirmed that the probability of maintaining primary and hematocrit (Hct) responses with rux treatment was 92% and 89%, respectively, and hence, rux could be an effective long-term therapy option for hydroxyurea (HU)-resistant/intolerant (R/I) pts with PV. Here, we report the long-term efficacy and safety updates of rux treatment in RESPONSE trial after a follow-up of 208 wks (after last pt first treatment visit). METHODS This was a preplanned follow-up when all pts completed the wk 208 visit or discontinued. Pts who were R/I of HU per modified ELN criteria, were aged ≥ 18 years (y), with splenomegaly, and phlebotomy (PBT) requirement to control Hct were eligible. Pts were randomized 1:1 to receive open-label rux 10 mg bid or BAT (selected based on investigator's choice). Pts randomized to BAT could crossover (CO) to rux after wk 32. The primary response was a composite endpoint of achieving both Hct control without PBT (defined as no PBT eligibility between wks 8 to 32 with no more than 1 PBT eligibility from randomization to wk 8) through wk 32 and a ≥ 35% of reduction in spleen volume (SVR) by imaging at wk 32. Durability of the primary response, overall clinicohematologic response (CLHM; Hct control without PBT, platelet count ≤ 400 × 109/L, a WBC count ≤ 10 × 109/L, SVR ≥ 35% by imaging) as well as the long-term safety were updated at wk 208 . RESULTS Overall, 222 pts were randomized (rux, 110; BAT, 112) and BL characteristics were overall similar between arms, though more pts randomized to rux had prior history of nonmelanoma skin cancer (NMSC) or pre-cancerous skin conditions (10.9 vs 6.3%) and longer prior exposure to HU (162.9 vs 145.6 wks) compared to BAT arm. At the wk 208 analysis, 41 pts (37%) originally randomized to rux arm were still receiving therapy (median exposure, 225 wks) vs no pts on BAT (median exposure, 34 wks). Among the pts in rux arm, 29% completed the treatment as per protocol. Of 98 pts who crossed over to rux after wk 32, 38% remained on rux (median exposure, 189 wks) and 31% completed treatment. Other main reasons for the study drug discontinuations (rux + CO pts) were disease progression (11% + 8%), pt decision (6% + 6%), and adverse events (AE, 14% + 14%). At the time of analysis in rux arm, 6 of 25 primary responders and 21 of 70 pt who achieved overall CLHM have progressed. Median duration of primary and CLHM responses has not been reached (Figure 1). The KM estimate at 208 wks of duration of primary and CLHM responses for rux arm are 0.73 (95% CI: 0.49, 0.87) and 0.67 (95% CI: 0.54, 0.77), respectively. The KM estimates for overall survival at 5 y were 90.6% (95% CI: 80.1, 95.7) in the rux arm and 87.7% (95% CI: 74.8, 94.3) in the BAT arm. Since wk 80 in rux arm, there were 2 new on-treatment deaths (adenocarcinoma gastric [n = 1, investigator-suspected event to be related to study drug] and neoplasm malignant [n = 1, investigator assessed it not related to study drug]). In the CO population, there were 4 pts who died and had fatal AEs leading to 4 on-treatment deaths (not related to rux). The most frequent AEs (> 20%) in the rux arm (wk 208 vs wk 80) were anemia (35% vs 27%), pruritus (27% vs 20%), diarrhea (26% vs 20%), headache (23% vs 22%), arthralgia (22% vs 13%), weight increased (21% vs 16%), and muscle spasms (20% vs 16%). The most frequent AE (> 20%) in CO pts (wk 208 vs wk 80) was anemia (29.6% vs 22.4%). In the rux arm and CO pts, incidence of thromboembolic events (wk 208 vs wk 80) was 4.5% vs 6% and 9.2% vs 6.1%. The exposure-adjusted rate of overall malignancies in rux was 6.8 (wk 208) vs 6.1 (wk 80) per 100 pt-ys and 4.5 per 100 pt-ys in CO pts (wk 208).The exposure-adjusted rate of NMSC in rux was 5.1 (wk 208) vs 4.4 (wk 80) per 100 pt-ys. In the CO pts, exposure-adjusted rate of NMSC was 2.6 (wk 208) vs 2.0 (wk 80) per 100 pt-ys. At wk 208, the rates of transformation to MF and AML in rux arm were 2.2 and 0.2 per 100 pt-yrs, respectively, and 1.9 and 0.3 in CO pts. CONCLUSION At wk 208 analysis of data from RESPONSE study, the overall safety profile remained consistent with the 80-wk data, and the response was durable. In both the rux arm and CO population, around 30% of pts completed the study treatment and 37% of pts were still receiving the treatment. Download : Download high-res image (82KB) Download : Download full-size image Disclosures Kiladjian: Celgene: Membership on an entity's Board of Directors or advisory committees; AOP Orphan: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding. Verstovsek: Roche: Research Funding; Roche: Research Funding; Blueprint Medicines Corp: Research Funding; Genentech: Research Funding; Seattle Genetics: Research Funding; Astrazeneca: Research Funding; Blueprint Medicines Corp: Research Funding; Gilead: Research Funding; Astrazeneca: Research Funding; Lilly Oncology: Research Funding; Seattle Genetics: Research Funding; Promedior: Research Funding; Incyte: Research Funding; CTI BioPharma Corp: Research Funding; CTI BioPharma Corp: Research Funding; Promedior: Research Funding; Celgene: Research Funding; Incyte: Research Funding; Celgene: Research Funding; Pfizer: Research Funding; Pfizer: Research Funding; Bristol Myers Squibb: Research Funding; Galena BioPharma: Research Funding; Genentech: Research Funding; Galena BioPharma: Research Funding; Lilly Oncology: Research Funding; NS Pharma: Research Funding; Bristol Myers Squibb: Research Funding; NS Pharma: Research Funding; Gilead: Research Funding. Griesshammer: Baxalta: Consultancy, Honoraria, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau; AOP Orphan: Consultancy, Honoraria, Speakers Bureau; Shire: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau. Masszi: BMS: Consultancy; Janssen-Cilag: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Takeda: Consultancy; AbbVie: Consultancy. Durrant: Novartis: Honoraria, Speakers Bureau. Passamonti: Novartis Pharmaceuticals Corporation: Consultancy, Honoraria, Speakers Bureau. Harrison: Gilead: Consultancy, Speakers Bureau; Shire: Speakers Bureau; Celgene: Consultancy; Novartis: Honoraria, Research Funding, Speakers Bureau; CTI: Speakers Bureau. Pane: Novartis: Honoraria, Speakers Bureau. Kirito: Novartis Pharma KK: Honoraria. Besses: Novartis: Honoraria, Research Funding; Shire: Honoraria. Hino: Novartis: Research Funding. Varela: Novartis: Honoraria, Speakers Bureau. Miller: Novartis: Honoraria, Speakers Bureau; Gilead: Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding, Speakers Bureau. Mesa: CTI BioPharma Corp.: Research Funding; Gilead Sciences, Inc.: Research Funding; Incyte Corporation: Research Funding; Ariad: Consultancy; Promedico: Research Funding; Celgene Corporation: Research Funding; Galena Biopharma, Inc.: Consultancy; Novartis Pharmaceuticals Corporation: Consultancy. Dong: Novartis: Employment. Francillard: Novartis: Employment. Laughlin: Novartis: Employment. Vannucchi: Novartis: Honoraria, Speakers Bureau; Shire: Speakers Bureau." @default.
• W2783012969 created "2018-01-26" @default.
• W2783012969 creator A5001816724 @default.
• W2783012969 creator A5003113496 @default.
• W2783012969 creator A5006360930 @default.
• W2783012969 creator A5008609620 @default.
• W2783012969 creator A5009381933 @default.
• W2783012969 creator A5019241495 @default.
• W2783012969 creator A5028552390 @default.
• W2783012969 creator A5036582191 @default.
• W2783012969 creator A5039057642 @default.
• W2783012969 creator A5046772202 @default.
• W2783012969 creator A5046827092 @default.
• W2783012969 creator A5047003547 @default.
• W2783012969 creator A5054160813 @default.
• W2783012969 creator A5054976477 @default.
• W2783012969 creator A5057084037 @default.
• W2783012969 creator A5060295441 @default.
• W2783012969 creator A5072484806 @default.
• W2783012969 creator A5085521139 @default.
• W2783012969 creator A5087587555 @default.
• W2783012969 creator A5087934925 @default.
• W2783012969 creator A5089940133 @default.
• W2783012969 creator A5090470146 @default.
• W2783012969 date "2017-12-07" @default.
• W2783012969 modified "2023-10-03" @default.
• W2783012969 title "Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)" @default.
• W2783012969 doi "https://doi.org/10.1182/blood.v130.suppl_1.322.322" @default.
• W2783012969 hasPublicationYear "2017" @default.
• W2783012969 type Work @default.
• W2783012969 sameAs 2783012969 @default.
• W2783012969 citedByCount "0" @default.
• W2783012969 crossrefType "journal-article" @default.
• W2783012969 hasAuthorship W2783012969A5001816724 @default.
• W2783012969 hasAuthorship W2783012969A5003113496 @default.
• W2783012969 hasAuthorship W2783012969A5006360930 @default.
• W2783012969 hasAuthorship W2783012969A5008609620 @default.
• W2783012969 hasAuthorship W2783012969A5009381933 @default.
• W2783012969 hasAuthorship W2783012969A5019241495 @default.
• W2783012969 hasAuthorship W2783012969A5028552390 @default.
• W2783012969 hasAuthorship W2783012969A5036582191 @default.
• W2783012969 hasAuthorship W2783012969A5039057642 @default.
• W2783012969 hasAuthorship W2783012969A5046772202 @default.
• W2783012969 hasAuthorship W2783012969A5046827092 @default.
• W2783012969 hasAuthorship W2783012969A5047003547 @default.
• W2783012969 hasAuthorship W2783012969A5054160813 @default.
• W2783012969 hasAuthorship W2783012969A5054976477 @default.
• W2783012969 hasAuthorship W2783012969A5057084037 @default.
• W2783012969 hasAuthorship W2783012969A5060295441 @default.
• W2783012969 hasAuthorship W2783012969A5072484806 @default.
• W2783012969 hasAuthorship W2783012969A5085521139 @default.
• W2783012969 hasAuthorship W2783012969A5087587555 @default.
• W2783012969 hasAuthorship W2783012969A5087934925 @default.
• W2783012969 hasAuthorship W2783012969A5089940133 @default.
• W2783012969 hasAuthorship W2783012969A5090470146 @default.
• W2783012969 hasConcept C126322002 @default.
• W2783012969 hasConcept C143998085 @default.
• W2783012969 hasConcept C2776112149 @default.
• W2783012969 hasConcept C2778837598 @default.
• W2783012969 hasConcept C2780007613 @default.
• W2783012969 hasConcept C2780076729 @default.
• W2783012969 hasConcept C71924100 @default.
• W2783012969 hasConceptScore W2783012969C126322002 @default.
• W2783012969 hasConceptScore W2783012969C143998085 @default.
• W2783012969 hasConceptScore W2783012969C2776112149 @default.
• W2783012969 hasConceptScore W2783012969C2778837598 @default.
• W2783012969 hasConceptScore W2783012969C2780007613 @default.
• W2783012969 hasConceptScore W2783012969C2780076729 @default.
• W2783012969 hasConceptScore W2783012969C71924100 @default.
• W2783012969 hasLocation W27830129691 @default.
• W2783012969 hasOpenAccess W2783012969 @default.
• W2783012969 hasPrimaryLocation W27830129691 @default.
• W2783012969 hasRelatedWork W112559982 @default.
• W2783012969 hasRelatedWork W157430056 @default.
• W2783012969 hasRelatedWork W2474660085 @default.
• W2783012969 hasRelatedWork W2900733038 @default.
• W2783012969 hasRelatedWork W2907253832 @default.
• W2783012969 hasRelatedWork W2907838543 @default.
• W2783012969 hasRelatedWork W2963919384 @default.
• W2783012969 hasRelatedWork W2977426574 @default.
• W2783012969 hasRelatedWork W2978676475 @default.
• W2783012969 hasRelatedWork W2979132948 @default.
• W2783012969 hasRelatedWork W2980701266 @default.
• W2783012969 hasRelatedWork W2989177065 @default.
• W2783012969 hasRelatedWork W2990419345 @default.
• W2783012969 hasRelatedWork W2990578343 @default.
• W2783012969 hasRelatedWork W3095073084 @default.
• W2783012969 hasRelatedWork W3095679320 @default.
• W2783012969 hasRelatedWork W3096486308 @default.
• W2783012969 hasRelatedWork W3096573094 @default.
• W2783012969 hasRelatedWork W3159084279 @default.
• W2783012969 hasRelatedWork W84221740 @default.
• W2783012969 hasVolume "130" @default.
• W2783012969 isParatext "false" @default.
• W2783012969 isRetracted "false" @default.
• W2783012969 magId "2783012969" @default.
• W2783012969 workType "article" @default.